Tetanus Vaccine in the form of a suspension for injection.

Each 2 ml dose contains concentrated immunopurified tetanus toxoid (≥ 30 IU/ml*) adsorbed onto aluminium phosphate.

*IU: International Units

For the active immunisation of horses 5 months of age or older against tetanus to prevent mortality.

Onset of immunity is within 2 weeks of completion of the primary course, with duration of immunity of at least 36 months.

2 ml

Equip T should be shaken thoroughly before use and administered by deep intramuscular injection.

Two injections of 2 ml with an interval of 4-6 weeks between them.

One dose should be given 36 months after the primary course, repeated at intervals of up to 36 months.

The efficacy of active immunisation of young foals against tetanus will be influenced by the level of maternally derived antibodies. This will vary between individuals due to a number of factors, e.g. the immune status of the dam; adequacy of colostral intake by the foal, etc. The vaccine should not be used in foals below 5 months of age, and foals should not be vaccinated until maternally derived antibodies have fallen below protective levels.

The vaccine may be used in pregnant mares which have been vaccinated against tetanus before pregnancy. Heavily pregnant mares should not be subjected to undue stress when vaccinated.

Do not use in unhealthy animals.

The product should be administered by respecting appropriate (aseptic) injection technique.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Do not mix with any other veterinary medicinal product.

Rarely (<1 in 1000) animals may exhibit a reaction to vaccination. This may be manifest by stiffness, a mild, transient rise in temperature, typically 9-12 hours post vaccination, or a small soft, non-painful local swelling (10-20 mm in diameter) at the injection site. These conditions normally resolve by the day following vaccination.

Injection site pain has been reported in very rare cases (<1 in 10,000).

Occasional hypersensitivity reactions may occur. In the event of an allergic or anaphylactic reaction, immediate treatment should be given with a soluble glucocorticoid intravenously or adrenalin intramuscularly.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Zero days.

Store in a refrigerator (2°C to 8°C). Protect from light. Do not freeze.

Keep out of the sight and reach of children.

For animal treatment only.

Packs with 10 x 2 ml doses. Each pack contains ten sterile disposable 2 ml syringes and 10 sterile needles.

In any animal population there may be a small number of individuals which fail to respond fully to vaccination. Successful vaccination depends upon correct storage and administration of the vaccine together with the animal's ability to respond. This can be influenced by such factors as genetic constitution, intercurrent infection, age, the presence of maternally derived antibodies, nutritional status, concurrent drug therapy and stress.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.